SULFAMYLON 5% TOPICAL SOLUTION Rx
Generic Name and Formulations:
Mafenide acetate 50g/packet; pwd for reconstitution (5% soln after mixing).
Indications for SULFAMYLON 5% TOPICAL SOLUTION:
Adjunct to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.
Adults and Children:
<3months: not recommended. ≥3months: Cover grafted area with one layer of fine mesh gauze. Cut an eight-ply burn dressing to the size of graft, wet with solution using an irrigation syringe and/or tubing until noticeable leaking. Maintain moisture with irrigation tubing (see literature) or wet dressing every 6–8 hours as needed. May leave wound dressings undisturbed for up to 5 days, except when irrigating. Additional soaks may be initiated until graft take is complete. Continue treatment until autograft vascularization and healing is progressing (approx. 5 days). Individual grafting procedure: max 5 days. Withhold therapy for 24–48 hours if acidosis occurs.
G6PD deficiency. Sulfite sensitivity. Asthma. Acute renal failure. Monitor acid-base balance closely (esp. with extensive 2nd degree or partial thickness burns, pulmonary or renal impairment). Pregnancy (Cat.C); (crm: not recommended for women of childbearing potential; unless burn area >20% of total body surface). Nursing mothers: not recommended.
Application-site pain, burning sensation, allergic manifestations (eg, rash, pruritus, facial edema, swelling, erythema; discontinue if occur), tachypnea, hyperventilation, metabolic acidosis; respiratory alkalosis, fatal hemolytic anemia with disseminated intravascular coagulation, fungal colonization; rare: excoriation of new skin, bleeding of skin.
Crm—2oz, 4oz, 16oz
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC